Short ELYMA short at 4.25 to 3.14 with the necessary risk management will bring a 26.18%+ return 3.2+ million volume. Strong resistance at 4.75
−1.31USD
−35.12 MUSD
18.44 M
About Eliem Therapeutics, Inc
Sector
Industry
CEO
Andrew D. Levin
Website
Headquarters
Wilmington
Employees (FY)
9
Founded
2018
ISIN
US28658R1068
FIGI
BBG00ZNKL0K6
Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its clinical-stage candidates are ETX-810 and ETX-155. ETX-810 is a novel palmitoylethanolamide (PEA) prodrug initially being developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy. ETX-155 is a neurosteroid GABAA receptor positive allosteric modulator (PAM) initially being developed for major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizures. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wilmington, DE.
Eliem Therapeutics All in One! ELYMPharma picks are kicking ass today.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere frac
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ELYM is 4.18 USD — it has decreased by 5.64% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Eliem Therapeutics, Inc stocks are traded under the ticker ELYM.
Eliem Therapeutics, Inc is going to release the next earnings report on May 13, 2024. Keep track of upcoming events with our Earnings Calendar.
ELYM stock is 9.22% volatile and has beta coefficient of −0.98. Check out the list of the most volatile stocks — is Eliem Therapeutics, Inc there?
ELYM earnings for the last quarter are −0.29 USD whereas the estimation was −0.38 USD which accounts for 23.68% surprise. Estimated earnings for the next quarter are −0.25 USD. See more details about Eliem Therapeutics, Inc earnings.
Yes, you can track Eliem Therapeutics, Inc financials in yearly and quarterly reports right on TradingView.
ELYM stock has risen by 4.24% compared to the previous week, the month change is a 56.39% rise, over the last year Eliem Therapeutics, Inc has showed a 29.81% increase.
ELYM net income for the last quarter is −3.64 M USD, while the quarter before that showed −3.97 M USD of net income which accounts for 8.24% change. Track more Eliem Therapeutics, Inc financial stats to get the full picture.
Today Eliem Therapeutics, Inc has the market capitalization of 122.80 M, it has decreased by 4.27% over the last week.
No, ELYM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ELYM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Eliem Therapeutics, Inc stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 9.00 employees. See our rating of the largest employees — is Eliem Therapeutics, Inc on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Eliem Therapeutics, Inc technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Eliem Therapeutics, Inc stock shows the buy signal. See more of Eliem Therapeutics, Inc technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.